Nature Medicine Publishes First Study Utilizing NanoString’s GeoMx Digital Spatial Profiler Whole Transcriptome Atlas

Rhea-AI Summary

NanoString Technologies (NASDAQ:NSTG) has announced a significant advancement in cancer research with the publication of a study in Nature Medicine utilizing its GeoMx® Digital Spatial Profiler (DSP) and Whole Transcriptome Atlas (WTA). Conducted by the Broad Institute, the study focuses on profiling sarcoma tissue and reveals novel insights into the immune response against synovial sarcoma. This peer-reviewed paper demonstrates GeoMx's capacity for high-plex spatial analysis, highlighting opportunities for future immunotherapy development.

Positive

• Publication in a prestigious journal enhances credibility.
• The study demonstrates the unique capabilities of the GeoMx DSP and WTA, positioning NanoString as a leader in spatial biology.
• Potential for the development of new immunotherapies based on findings.

Negative

• None.

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of a study in the journal Nature Medicine that used NanoString’s GeoMx® Digital Spatial Profiler (DSP) and the new Whole Transcriptome Atlas (WTA) to profile sarcoma tissue. The research was led by a team from the Broad Institute in Cambridge, Massachusetts. The paper, entitled “Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma,” can be found here.(https://www.nature.com/articles/s41591-020-01212-6)

Nature Medicine publishes first peer-reviewed study using GeoMx DSP with next generation sequencing readout. (Photo: Business Wire)

In this work, researchers used the unique segmentation capability of the GeoMx Digital Spatial Profiler to subdivide regions within the tumors into distinct immune and tumor compartments and interrogate them using the GeoMx Whole Transcriptome Atlas. The use of high-plex spatial profiling allowed researchers to observe a negative correlation between the core oncogenic program and immune response, which may ultimately provide insights that lead to the development of novel immunotherapies for synovial sarcomas.

“The ability to segment and interrogate distinct segments with a high-plex platform allowed us to delineate the spatial connection between the malignant cells' states and their microenvironment in the intact tissue,” stated Livnat Jerby-Arnon, Assistant Professor at Stanford University and Chan Zuckerberg Biohub Investigator. "The scope of the GeoMx Whole Transcriptome Atlas was particularly important because it allowed us to explore the spatial distribution of hundreds of genes from readily available FFPE samples.”

“We’re proud to highlight the first peer reviewed publication demonstrating the unique capabilities of our GeoMx Whole Transcriptome Atlas for spatial analysis,” said Brad Gray, NanoString’s president and chief executive officer. “The launch of our WTA assay will expand our spatial portfolio beyond focused panels, opening up vast new opportunities in biological research.”

The GeoMx Digital Spatial Profiler enables researchers to rapidly and quantitatively characterize tissue morphology with a high-throughput, high-plex RNA and protein profiling system that preserves samples for future analyses. NanoString and its collaborators have published DSP data in more than 38 peer-reviewed papers and presented DSP data in numerous abstracts at major scientific meetings, demonstrating the utility of DSP technology to address a wide range of biological questions with robust performance in a broad variety of sample types, including Formalin-Fixed Paraffin-Embedded (FFPE) tissue.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for translational research. The company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 4,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s GeoMx Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005225/en/

FAQ

What is the significance of the study published in <i>Nature Medicine</i> by NanoString Technologies?

The study demonstrates the application of NanoString's GeoMx DSP and Whole Transcriptome Atlas in profiling sarcoma tissue, providing insights for potential immunotherapy developments.

Who led the research published by NanoString Technologies?

The research was led by a team from the Broad Institute in Cambridge, Massachusetts.

What technology did NanoString Technologies use in the published study?

The study utilized NanoString's GeoMx® Digital Spatial Profiler and Whole Transcriptome Atlas for high-plex spatial analysis.

How does the GeoMx Digital Spatial Profiler benefit cancer research?

It allows researchers to characterize tissue morphology and examine the spatial distribution of genes and proteins, offering insights into tumor microenvironments.